首页> 外文期刊>Clinical investigation >Translational biomarker in oncology early clinical development: decision case study for MEK inhibitors in healthy volunteer studies
【24h】

Translational biomarker in oncology early clinical development: decision case study for MEK inhibitors in healthy volunteer studies

机译:肿瘤学早期临床开发中的转化生物标志物:健康志愿者研究中MEK抑制剂的决策案例研究

获取原文
获取原文并翻译 | 示例
           

摘要

Biomarkers of drug activity are increasingly important tools in oncology early drug development, particularly in this era of targeted therapies. In early development, their main use is to help select the best drugs and/or dosing regimens to progress in development. The case study demonstrates how a biomarker of molecular target activity was developed in a preclinical setting and translated into the clinic to assess the 'proof of mechanism' for two competing MEK inhibitors, CH4987655 and RO5068760. Inhibition of ERK phosphorylation (pERK) was measured using a surrogate tissue, ex vivo phorbol 12-myristate 13-acetate-stimulated peripheral blood mononuclear cells. CH4987655 demonstrated concentration-dependent pERK inhibition with exposures covering pERK inhibition from the no effect level to near maximum effect of 100%. However, RO5068760 demonstrated a rather modest pERK inhibition of only 55%. The biomarker demonstrated CH4987655 was superior in terms of MEK inhibition and the potential for therapeutic effects enabled the choice to progress only CH4987655 into
机译:药物活性的生物标志物在肿瘤学早期药物开发中越来越重要,尤其是在这种靶向治疗时代。在早期开发中,它们的主要用途是帮助选择最佳的药物和/或给药方案以促进开发。案例研究表明,如何在临床前环境中开发分子靶标活性的生物标记物,并将其转化为临床,以评估两种竞争性MEK抑制剂CH4987655和RO5068760的“机理证明”。使用替代组织,离体佛波醇12-肉豆蔻酸酯13-醋酸酯刺激的外周血单核细胞测量ERK磷酸化(pERK)的抑制作用。 CH4987655表现出浓度依赖性的pERK抑制作用,其暴露范围涵盖了pERK抑制作用,从无影响水平到接近最大作用100%。然而,RO5068760表现出相当适度的pERK抑制,仅为55%。生物标志物证明,CH4987655在抑制MEK方面具有优越性,并且具有治疗效果的潜力使该选择仅使CH4987655进入了

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号